Antifungal activity of LY303366, a novel echinocandin B, in experimental disseminated candidiasis in rabbits.
about
In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazoleEfficient bioconversion of echinocandin B to its nucleus by overexpression of deacylase genes in different host strainsPharmacokinetics and pharmacodynamics of antifungals in children: clinical implicationsRapamycin and less immunosuppressive analogs are toxic to Candida albicans and Cryptococcus neoformans via FKBP12-dependent inhibition of TORProtective effect of a novel antifungal peptide derived from human chromogranin a on the immunity of mice infected with Candida krusei.Efficacy, plasma pharmacokinetics, and safety of icofungipen, an inhibitor of Candida isoleucyl-tRNA synthetase, in treatment of experimental disseminated candidiasis in persistently neutropenic rabbits.Dosage-dependent antifungal efficacy of V-echinocandin (LY303366) against experimental fluconazole-resistant oropharyngeal and esophageal candidiasis.Compartmental pharmacokinetics of the antifungal echinocandin caspofungin (MK-0991) in rabbits.Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma samplingCompartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits.Anidulafungin compared with fluconazole for treatment of candidemia and other forms of invasive candidiasis caused by Candida albicans: a multivariate analysis of factors associated with improved outcome.Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections.Safety and pharmacokinetics of multiple-dose anidulafungin in infants and neonatesPharmacodynamic target evaluation of a novel oral glucan synthase inhibitor, SCY-078 (MK-3118), using an in vivo murine invasive candidiasis model.Pharmacodynamics of echinocandins against Candida glabrata: requirement for dosage escalation to achieve maximal antifungal activity in neutropenic hostsAnidulafungin for neonatal hematogenous Candida meningoencephalitis: identification of candidate regimens for humans using a translational pharmacological approach.Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization.Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis: review of the literatureIn vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model.Antifungal agents and therapy for infants and children with invasive fungal infections: a pharmacological perspective.Antifungal agents commonly used in the superficial and mucosal candidiasis treatment: mode of action and resistance developmentEfficacy of PLD-118, a novel inhibitor of candida isoleucyl-tRNA synthetase, against experimental oropharyngeal and esophageal candidiasis caused by fluconazole-resistant C. albicans.In vitro activity of anidulafungin against selected clinically important mold isolatesAnidulafungin: an evidence-based review of its use in invasive fungal infections.In vitro activity of anidulafungin and other agents against esophageal candidiasis-associated isolates from a phase 3 clinical trial.Pharmacodynamics of the Long Acting Echinocandin, CD101, in the Neutropenic Invasive Candidiasis Murine Model Using an Extended Interval Dosing Design.
P2860
Q24538858-C7B64976-82B2-4AD2-A58E-18ACADDD17CCQ24623710-276FC01F-9F9A-463C-8A70-5FD44A57BBB4Q27025299-A6272DE3-4312-4FC6-B590-12807D809997Q28361576-710AA617-E662-4545-8CA5-1687843851CFQ33724155-FC26B7A9-538D-459E-A291-547C48439D3CQ33770019-77704D2A-CE72-4A97-B2ED-C360411E6E91Q33981387-439A46D8-D8DE-4D1F-8862-05C1F2339A26Q33981480-5E6112AF-3A1E-4305-B1C8-998F19E38C46Q33983159-EEF13A98-DB12-4BBA-B900-F9B2FCED9FC2Q33983506-7EA005FE-ED65-4DF0-B844-26EECA00D6F7Q34036214-E03C1CBD-D885-48E9-997B-819BF9C567E9Q34352100-104BA5DB-EA69-4568-8A0A-AD4378E19431Q35071572-CEBB3B30-577D-4826-8653-4319B63ACB15Q35105763-04E3A36A-D58C-4685-86DC-903A2937394DQ35270758-33B661B0-48AF-4115-805C-49F0B42C417FQ35689202-226D3FC8-6BF8-45CF-A019-E7CD5CE7BAA7Q35745822-EFB9E6DD-00DB-499B-80DE-2D5FD3055301Q35959484-B899989E-813E-4D1B-B84C-D75C532A8C18Q36425025-25557A99-21A6-4352-B19C-123D339487B8Q36948094-D6FF0A4B-BE5C-439D-A307-77F47B7708D7Q37381931-FC700781-30AA-4538-AA48-750C3646FA1BQ37568979-A0487EED-BFD7-4E06-B9B7-34C85B374F2DQ37734590-1A09342E-E3B9-4042-8B67-433A468D7F3DQ37827345-0C77BC61-861A-4240-8775-3205599894EAQ41867739-5B183FA9-B5EB-4F15-90FD-ED6183AFE1ABQ46248423-C78FE2E0-2892-4180-B3F4-B0556E6340AA
P2860
Antifungal activity of LY303366, a novel echinocandin B, in experimental disseminated candidiasis in rabbits.
description
1999 nî lūn-bûn
@nan
1999 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Antifungal activity of LY30336 ...... inated candidiasis in rabbits.
@ast
Antifungal activity of LY30336 ...... inated candidiasis in rabbits.
@en
type
label
Antifungal activity of LY30336 ...... inated candidiasis in rabbits.
@ast
Antifungal activity of LY30336 ...... inated candidiasis in rabbits.
@en
prefLabel
Antifungal activity of LY30336 ...... inated candidiasis in rabbits.
@ast
Antifungal activity of LY30336 ...... inated candidiasis in rabbits.
@en
P2093
P2860
P1476
Antifungal activity of LY30336 ...... inated candidiasis in rabbits.
@en
P2093
C L McMillian
M Candelario
R Petraitiene
V Petraitis
P2860
P304
P407
P577
1999-09-01T00:00:00Z